OmnicellMEX:OMCL 68 Days Payable is 27.52 as of Mar. 2026, which is 17% below its 10-year median of 33.26. GuruFocus rates MEX:OMCL with a GF Score™ of 68/100 and a GF Value™ of MXN736.07 (Fairly Valued). The stock has 6 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Omnicell ranks worse than 74.92% on this metric.
Omnicell's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN922 Mil. Omnicell's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN3,057 Mil.
Hence, Omnicell's Days Payable for the
three
months ended in Mar. 2026 was 27.52.
The historical rank and industry rank for Omnicell's Days Payable or its related term are showing as below:
MEX:OMCL'
s Days Payable Range Over the Past 10 Years
Min: 23.95 Med: 33.26 Max: 37.97
Current: 29.58
During the past 13 years, Omnicell's highest Days Payable was 37.97. The lowest was 23.95. And the median was 33.26.
MEX:OMCL's Days Payable is ranked worse than 74.92% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs MEX:OMCL: 29.58
Omnicell's Days Payable
declined
from Mar. 2025 (30.49) to Mar. 2026 (27.52).
It may suggest that Omnicellaccelerated paying its suppliers.
Omnicell Days Payable Related Terms
Omnicell Days Payable Historical Data
* Premium members only.
The historical data trend for Omnicell's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:OMCL vs TDOC, SDGR, OMDA: Days Payable Comparison
For the Health Information Services subindustry, Omnicell's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Days Payable distribution charts can be found below:
* The bar in red indicates where Omnicell's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Omnicell's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell (MEX:OMCL) has a Days Payable of 27.52 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Omnicell and its competitors. This is 17% below median its historical median of 33.26. Over the past decade, Omnicell's Days Payable has ranged from 23.95 to 37.97. According to the industry distribution chart, Omnicell ranks #454 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 74.9%.
Is Omnicell's Days Payable too high?
Omnicell's current Days Payable of 27.52 is 17% below median its 10-year median of 33.26. Over the past 10 years, this metric has ranged from a low of 23.95 to a high of 37.97. The Healthcare Providers & Services industry median Days Payable is 58.21. Omnicell's value of 27.52 is 52.7% below this industry median. Based on the distribution chart, Omnicell ranks #454 out of 606 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Omnicell has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Days Payable compare to TDOC and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #454 out of 606 companies for Days Payable. This places Omnicell in the lower half of its industry. The industry median Days Payable is 58.21. Omnicell's value of 27.52 is 52.7% below this benchmark. Historically, Omnicell's own Days Payable has ranged from 23.95 to 37.97 over the past decade. While the company's 10-year median is 33.26 vs. the industry median of 58.21, Omnicell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current Days Payable of 27.52 is 52.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current Days Payable is 27.52, which is 17% below median its own 10-year median of 33.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Based on GuruFocus' analysis, Omnicell (MEX:OMCL) is currently considered Fairly Valued. The stock's GF Value™ is MXN736.07, compared to a current price of MXN761.16 — trading 3.4% above its estimated fair value. The current Days Payable is 27.52, which is 17% below median its 10-year median of 33.26 and 52.7% below the Healthcare Providers & Services industry median of 58.21. Omnicell's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current Days Payable is 27.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be overvalued.
The current stock price of MXN761.16 is trading 3.4% above its estimated GF Value™ of MXN736.07.
GuruFocus considers Omnicell to be Fairly Valued.
Key valuation signals for MEX:OMCL:
Days Payable: 27.52 (17% below median its 10-year median of 33.26)
GF Value™: MXN736.07 vs. price of MXN761.16 (3.4% above fair value)
Industry Position: 52.7% below the Healthcare Providers & Services median (#454 of 606)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
68GF Score
Get the complete analysis for MEX:OMCL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
